Latest1 information on COVID-19

Clinical Trials Contact

About this Clinical Trial

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Your Message Will Go To

Elizabeth Winters

+1 650-721-6509


All fields are required. *

Preferred contact method*

To:

Elizabeth Winters

+1 650-721-6509



Go Back To The Trial

We were not able to send your contact info at this time.

Go Back To The Trial

©2022 Stanford Medicine